PD-1 Antikörper (PE)

Produktnummer ABIN2663970

Dieses Maus Monoklonal-Antikörper erkennt spezifisch PD-1 in ICFC. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für PD-1 Antikörper (PE) (ABIN2663970)

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PD-1 Antikörper ist konjugiert mit PE

Applikation: Intracellular Flow Cytometry (ICFC)

Klon: EH12-2H7

Produktdetails anti-PD-1 Antikörper (PE)

Kreuzreaktivität: Schimpanse, Marmoset, Rhesusaffen, Squirrel Monkey (Saimiri spec.), Cynomolgus

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu PD-1

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Andere Bezeichnung: CD279

Hintergrund: Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Pathways: Cancer Immune Checkpoints